We have developed a first-in-class technology platform to create novel hybrid interferons, designed to deliver pleiotropic drug candidates engineered for reduced toxicity and improved efficacy.

Our platform can rationally design, select and develop novel hybrid interferon candidates, engineering highly specific proteins that harness and enhance favourable the diversity of natural IFNs to treat diseases with unmet medical needs.

Across infectious, inflammatory, autoimmune and cancerous diseases, targeted medicines are increasingly used in combination therapies to treat all aspects of disease.

Hybrid interferons have the potential to act on multiple targets in complex diseases, giving them a broader spectrum of activity compared with monoclonal antibodies or small molecules.

We have a growing body of pre-clinical data demonstrating the safety and efficacy profile of our hybrid interferon candidates.

All IP is wholly owned by ILC Therapeutics, including granted patents providing robust coverage of the Company’s candidates and their use, with coverage spanning across many territories including the EU and USA.

ILCT's platform selects domains from IFN subtypes to create Hybrid IFNs